ABP1019A / AB Pharma - LARVOL DELTA

A phase I clinical trial of ABP1019A monotherapy in patients with advanced malignant solid tumors. (ASCO 2025) - P1 | "Importantly, it exhibits broader superior inhibitory activity compared to Lenvatinib and Regorafenib. The results of ABP1019A in phase I dose escalation study showed that this monotherapy was well tolerated, and had preliminary anti-tumor efficacy on advanced pancreatic cancer, glioma, lung and thyroid cancer, etc. A phase II exploratory study is ongoing to further verify the safety and anti-tumor efficacy of ABP1019A on 8 types of tumors including glioma, pancreatic cancer, osteosarcoma, cholangiocarcinoma, SCLC, colorectal cancer, esophageal cancer, and gastric cancer."

Clinical • Metastases • Monotherapy • P1 data • Biliary Cancer • Brain Cancer • Cholangiocarcinoma • Colorectal Cancer • Endocrine Cancer • Esophageal Cancer • Gastric Cancer • Glioma • Lung Cancer • Oncology • Osteosarcoma • Pancreatic Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Thyroid Gland Carcinoma • CSF1R • EGFR • FLT1 • PDGFRA